Marie Sinclair

List of Publications by Year
in descending order

45 papers	1,184 citations	516215 16 h-index	377514 34 g-index
45 all docs	45 docs citations	45 times ranked	1566 citing authors

#	Article	IF	Citations
1	Review article: sarcopenia in cirrhosis â€“ aetiology, implications and potential therapeutic interventions. Alimentary Pharmacology and Therapeutics, 2016, 43, 765-777.	1.9	252
2	Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. Journal of Hepatology, 2016, 65, 906-913.	1.8	187
3	Testosterone in men with advanced liver disease: Abnormalities and implications. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 244-251.	1.4	114
4	Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist. World Journal of Gastroenterology, 2017, 23, 899.	1.4	107
5	Handgrip Strength Adds More Prognostic Value to the Model for Endâ€Stage Liver Disease Score Than Imagingâ€Based Measures of Muscle Mass in Men With Cirrhosis. Liver Transplantation, 2019, 25, 1480-1487.	1.3	68
6	Low testosterone as a better predictor of mortality than sarcopenia in men with advanced liver disease. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 661-667.	1.4	44
7	Risk factors for band-induced ulcer bleeding after prophylactic and therapeutic endoscopic variceal band ligation. European Journal of Gastroenterology and Hepatology, 2015, 27, 928-932.	0.8	35
8	Use of Dual Xâ€ray Absorptiometry in men with advanced cirrhosis to predict sarcopeniaâ€associated mortality risk. Liver International, 2019, 39, 1089-1097.	1.9	33
9	Additive impact of preâ€liver transplant metabolic factors on survival postâ€liver transplant. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1016-1024.	1.4	30
10	Malnutrition in cirrhosis: More food for thought. World Journal of Hepatology, 2020, 12, 883-896.	0.8	30
11	Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the model for endâ€stage liver disease score. Liver Transplantation, 2016, 22, 1482-1490.	1.3	23
12	Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. Clinical Infectious Diseases, 2021, 73, e3288-e3295.	2.9	21
13	Controversies in Diagnosing Sarcopenia in Cirrhosisâ€”Moving from Research to Clinical Practice. Nutrients, 2019, 11, 2454.	1.7	20
14	Epidemiology and outcomes of acute liver failure in Australia. World Journal of Hepatology, 2019, 11, 586-595.	0.8	20
15	High circulating oestrone and low testosterone correlate with adverse clinical outcomes in men with advanced liver disease. Liver International, 2016, 36, 1619-1627.	1.9	17
16	Stopping nucleot(s)ide analogues in nonâ€cirrhotic <scp>HBeAg</scp>â€negative chronic hepatitis B patients: <scp>HBsAg</scp> loss at 96â€‰weeks is associated with low baseline <scp>HBsAg</scp> levels. Alimentary Pharmacology and Therapeutics, 2022, 56, 310-320.	1.9	16
17	Nutraceuticals for the treatment of sarcopenia in chronic liver disease. Clinical Nutrition ESPEN, 2021, 41, 13-22.	0.5	15
18	Regression of hepatocellular adenomas and systemic inflammatory syndrome after cessation of estrogen therapy. Hepatology, 2017, 66, 989-991.	3.6	13

#	Article	IF	Citations
19	Continuous terlipressin infusion is associated with improved diet intake and muscle strength in patients awaiting liver transplant. JHEP Reports, 2019, 1, 107-113.	2.6	13
20	Women on the liver transplantation waitlist are at increased risk of hospitalization compared to men. World Journal of Gastroenterology, 2018, 25, 980-988.	1.4	13
21	Acute Hepatic Decompensation Precipitated by Pregnancy-Related Catabolic Stress. Obstetrics and Gynecology, 2014, 123, 480-483.	1.2	12
22	Exercise physiology in cirrhosis and the potential benefits of exercise interventions: A review. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2687-2705.	1.4	12
23	Malnutrition and low muscle strength are independent predictors of clinical outcomes and healthcare costs after liver transplant. Clinical Nutrition ESPEN, 2022, 48, 210-219.	0.5	12
24	Something fishy: an unusual Erysipelothrix rhusiopathiae infection in an immunocompromised individual. BMJ Case Reports, 2013, 2013, bcr2013008873-bcr2013008873.	0.2	10
25	Successful liver transplantation in common variable immune deficiency with reversal of hepatopulmonary syndrome. BMJ Case Reports, 2019, 12, e226095.	0.2	9
26	Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations. World Journal of Hepatology, 2022, 14, 754-765.	0.8	8
27	In reference to higher serum testosterone is associated with increased risk of advanced hepatitis c-related liver disease in males. Hepatology, 2012, 56, 2007-2007.	3.6	6
28	Safety and efficacy of outpatient continuous terlipressin infusion for the treatment of portal hypertensive complications in cirrhosis. European Journal of Gastroenterology and Hepatology, 2022, 34, 206-212.	0.8	6
29	Retreatment with elbasvir, grazoprevir, sofosbuvirÂÂ±Âribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse. Liver International, 2019, 39, 2285-2290.	1.9	5
30	Drug-induced liver failure due to rivaroxaban. Annals of Hematology, 2018, 97, 2267-2268.	0.8	4
31	Fibrosing Cholestatic Hepatitisâ€“Like Syndrome in an Immunocompetent Patient With an Acute Flare of Chronic Hepatitis B. Hepatology, 2019, 70, 1480-1483.	3.6	4
32	Muscle mass and mortality in chronic liver disease: The impact of testosterone. Liver Transplantation, 2014, 20, 504-505.	1.3	3
33	Low-Serum Testosterone Levels Pre-Liver Transplantation Are Associated With Reduced Rates of Early Acute Allograft Rejection in Men. Transplantation, 2014, 98, 788-792.	0.5	3
34	Letter to the Editor: Moderate Alcohol Use in Fatty Liver Disease: Donâ€™t Throw the Cabernet Out With the Bathwater. Hepatology, 2020, 71, 1887-1888.	3.6	3
35	Upcoming Pharmacological and Interventional Therapies for theÂTreatment of Physical Frailty and Sarcopenia. , 2020, , 211-232.		3
36	Moving computed tomographyâ€“based quantification of muscle mass to the mainstream: Validation of a webâ€based platform to calculate skeletal muscle index in cirrhosis. Liver Transplantation, 2022, 28, 1944-1946.	1.3	3

#	Article	IF	Citations
37	Management, outcomes and survival of an Australian IgG4â€SC cohort: The MOSAIC study. Liver International, 2021, 41, 2934-2943.	1.9	2
38	Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients. World Journal of Gastrointestinal Oncology, 2021, 13, 2149-2160.	0.8	2
39	Reduced upper limb lean mass on dual energy X-ray absorptiometry predicts adverse outcomes in male liver transplant recipients. World Journal of Transplantation, 2022, 12, 120-130.	0.6	2
40	Low participation in preventative health measures in a cohort of liver transplant recipients: A crossâ€sectional analysis. Clinical Transplantation, 2021, 35, e14257.	0.8	1
41	Determining Energy Requirements in Cirrhosis: an Update on the Role of Indirect Calorimetry. Current Hepatology Reports, 2021, 20, 85-95.	0.4	1
42	Letter: TIPSS is a promising therapy for sarcopenia in cirrhosis. Alimentary Pharmacology and Therapeutics, 2021, 53, 209-209.	1.9	1
43	Prevalence, severity, duration and resolution of cholestasis after acute liver failure. BMJ Open Gastroenterology, 2022, 9, e000801.	1.1	1
44	Reply. Liver Transplantation, 2020, 26, 309-310.	1.3	0
45	Caution Regarding Endoscopic Balloon Placement and the Risk of Sarcopenia in Liver Transplant Candidates. Liver Transplantation, 2022, 28, 730-731.	1.3	0